Quaid sues Baxter over twins' heparin overdose; Sigma taps Lazard for advice on Aspen bid;

 @FiercePharma: Moody's cuts outlook on Eli Lilly to 'negative'. Story | Follow @FiercePharma

> Dennis Quaid sued Baxter Healthcare over the life-threatening overdoses of heparin given his newborn twins three years ago; the actor has already settled with the hospital where the drug was administered. Report

> Sigma Pharmaceuticals hired Lazard Ltd. to advise it on a A$707 million ($580 million) takeover offer from Aspen Pharmacare, sources tell Bloomberg. Report

> Sun Pharmaceutical Industries reported a 26 percent drop in consolidated net profit for the year ended March 31 as regulatory issues in the U.S. hurt its performance in one of its largest markets. Report

> Abbott Laboratories on Monday sold $3 billion of senior unsecured notes, said IFR, a Thomson Reuters service. Report

> The Indian government plans to offer subsidies to medium-sized pharmaceutical firms to help them meet WHO manufacturing standards. Report

> Watson Pharmaceuticals got the FDA nod for a generic version of GlaxoSmithKline's herpes treatment Valtrex. Report

> The FDA and National Institutes of Health launched a new website that, when fully developed, will provide a mechanism for the reporting of pre- and post-market safety data to the federal government. Release

> British drugmaker GlaxoSmithKline spent just over $2.2 million lobbying the U.S. government on patent laws and other issues during the first quarter, according to a recent disclosure. Report

> Meanwhile, AstraZeneca spent $1.7 million in the first quarter lobbying in the U.S., according to its disclosure. Report

> Takeda appointed Kiyohiko Tamura as general manager of its newly established Office of the President & CEO. Report

Biotech News

 @FierceBiotech: GE brings $3B life sciences project to light. Report | Follow @FierceBiotech

 @JohnCFierce: Biosimilars, in many ways, will be even harder to test, often demanding comparative effectiveness studies with the branded biologic.| Follow @JohnCFierce

> Stem Cell Therapeutics shares blitzed after PhIIb stroke trial fails. Story

> Teva pioneering a biosimilar to compete with blockbuster Rituxan. Report

> Neurocrine shares skyrocket on promising PhII endometriosis data. News

Biotech Research News

> Who owns synthetic life forms? Report

> Singapore team offers new combo drug strategy to kill cancer cells. Story

> Australian state government touts latest research. News

> Gene therapy holds promise for muscular dystrophy patients. Article

> Stem cell team will recreate crippling brain disease in the lab. Story

Pharma Manufacturing News

> Regulators mull pros, cons of transparency efforts. Story

> Obama's advisors identify vaccine fixes. Report

> Expert tips for working with headhunters. Piece

> Intellipharmaceutics aims for abuse-deterrent painkiller. Article

> India arrests two in week of counterfeit drug raids. Report

> Students win prize for tobacco-plant vax process. Item

And Finally... A growing body of evidence links exercise and mental acuity. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.